Advertisement for orthosearch.org.uk
Results 1 - 4 of 4
Results per page:
Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_I | Pages 31 - 31
1 Mar 2010
Kakkar AK Muntz J Haas S Brenner B Dahl OE Eriksson BI Mouret P Bandel TJ Soglian AG
Full Access

Purpose: Venous thromboembolism (VTE) is a common, potentially fatal complication of major orthopaedic surgery. Pharmacologic thromboprophylaxis is recommended following total hip replacement (THR) for a minimum of 10 days, and up to 35 days. However, its extended use is not accepted universally – an effective, safe and convenient, oral anticoagulant would improve implementation of these recommendations. This study was conducted to compare short-term thromboprophylaxis with enoxaparin and extended thromboprophylaxis with the novel, oral, direct Factor Xa inhibitor rivaroxaban after THR. This was the largest, prospective, randomized clinical trial conducted to date for the evaluation of the risk/benefit of extended duration thromboprophylaxis.

Method: In this global, double-blind trial, 2509 patients undergoing THR were randomized to receive either subcutaneous enoxaparin 40 mg once daily (od), beginning the evening before surgery and continued for 10–14 days, followed by placebo until day 35±4 (short-term prophylaxis); or oral rivaroxaban 10 mg od beginning 6–8 hours after surgery and continuing for 35±4 days (extended prophylaxis). Mandatory, bilateral venography was conducted on day 36±4. The primary efficacy endpoint was the composite of any deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE), and all-cause mortality. The main secondary efficacy endpoint was major VTE; the composite of proximal DVT, non-fatal PE, and VTE-related death. Safety endpoints included the incidence of major and non-major bleeding.

Results: Extended thromboprophylaxis with rivaroxaban significantly reduced the incidence of both the primary efficacy endpoint (2.0% versus 9.3%, respectively; p< 0.001; relative risk reduction [RRR] 79%) and major VTE (0.6% versus 5.1%, respectively; p< 0.001; RRR 88%), compared with short-term enoxaparin. The incidence of major bleeding was 0.1% in patients receiving either extended or short-term thromboprophylaxis. Non-major bleeding was reported in 6.5% of patients receiving extended prophylaxis with rivaroxaban and 5.5% of those receiving short-term enoxaparin.

Conclusion: Extended duration thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin for the prevention of VTE in patients undergoing THR. Both regimens were associated with a similar incidence of bleeding. Extended thromboprophylaxis provides substantial benefits for patients undergoing THR and rivaroxaban provides a safe and effective option for this strategy.


The Journal of Bone & Joint Surgery British Volume
Vol. 90-B, Issue 2 | Pages 127 - 132
1 Feb 2008
Warwick D Dahl OE Fisher WD

Thromboprophylaxis remains a controversial subject. A vast amount of epidemiological and trial data about venous thromboembolism has been published over the past 40 years. These data have been distilled and synthesised into guidelines designed to help the practitioner translate this extensive research into ‘evidence-based’ advice.

Guidelines should, in theory, benefit patient care by ensuring that every patient routinely receives the best prophylaxis; without guidelines, it is argued, patients may fail to receive treatment or be exposed to protocols which are ineffective, dangerous or expensive.

Guidelines, however, have not been welcomed or applied universally. In the United States, orthopaedic surgeons have published their concerns about the thromboprophylaxis guidelines prepared by the American College of Chest Physicians. In Britain, controversy persists with many surgeons unconvinced of the risk/benefit, cost/benefit or practicality of thromboprophylaxis. The extended remit of the recent National Institute of Clinical Excellence thromboprophylaxis guidelines has been challenged.

The reasons for this disquiet are addressed in this paper and particular emphasis is placed on how clinically-acceptable guidelines could be developed and applied.


Orthopaedic Proceedings
Vol. 88-B, Issue SUPP_I | Pages 6 - 6
1 Mar 2006
Dahl OE
Full Access

Major bone surgery causes damage to the bone marrow cells and destruction of blood vessels. This induces a tremendous local and systemic thrombin generation. This may trigger vascular instability during surgery that in seldom cases may be fatal in susceptible patients in particular if bone cement is implanted. The overall mortality following elective hip replacement is low since the patients are selected for the procedure and medically optimized. Following emergency hip fracture surgery the patients are substantially older, many have co-morbid conditions and the mortality is markedly higher. Vascular events dominate. Pulmonary embolism, and myocardial infarction are prominent together with pneumonia (a condition that trigger the coagulation system).

Postoperatively, thrombin continues to be generated for a long time after surgery as a part of the inflammatory healing process. Vascular complications dominate and epidemiological studies have shown a general complication risk period lasting for nearly 3 months and significantly longer in subgroups. Although, mortality has decreased in recent years, morbidity continues to play an important and less focused role although with substantial health economic implications.


The Journal of Bone & Joint Surgery British Volume
Vol. 88-B, Issue 3 | Pages 386 - 391
1 Mar 2006
Bjørnar̊ BT Gudmundsen TE Dahl OE

Over a 13-year period we studied all patients who underwent major hip and knee surgery and were diagnosed with objectively confirmed symptomatic venous thromboembolism, either deep venous thrombosis or non-fatal pulmonary embolism, within six months after surgery. Low-molecular-weight heparin had been given while the patients were in hospital.

There were 5607 patients. The cumulative incidence of symptomatic venous thromboembolism was 2.7% (150 of 5607), of which 1.1% had developed pulmonary embolism, 1.5% had deep venous thrombosis and 0.6% had both. Patients presented with deep venous thrombosis at a median of 24 days and pulmonary embolism at 17 days after surgery for hip fracture. After total hip replacement, deep venous thrombosis and pulmonary embolism occurred at a median of 21 and 34 days respectively. After total knee replacement, the median time to the presentation of deep venous thrombosis and pulmonary embolism was 20 and 12 days respectively. The cumulative risk of venous thromboembolism lasted for up to three months after hip surgery and for one month after total knee replacement. Venous thromboembolism was diagnosed after discharge from hospital in 70% of patients who developed this complication.

Despite hospital-based thromboprophylaxis, most cases of clinical venous thromboembolism occur after discharge and at different times according to the operation performed.